Journal article

High Levels of Genomic Aberrations in Serous Ovarian Cancers Are Associated with Better Survival

Lars O Baumbusch, Aslaug Helland, Yun Wang, Knut Liestol, Marci E Schaner, Ruth Holm, Dariush Etemadmoghadam, Kathryn Alsop, Pat Brown, Gillian Mitchell, Sian Fereday, Anna DeFazio, David DL Bowtell, Gunnar B Kristensen, Ole Christian Lingjaerde, Anne-Lise Borresen-Dale



Genomic instability and copy number alterations in cancer are generally associated with poor prognosis; however, recent studies have suggested that extreme levels of genomic aberrations may be beneficial for the survival outcome for patients with specific tumour types. We investigated the extent of genomic instability in predominantly high-grade serous ovarian cancers (SOC) using two independent datasets, generated in Norway (n = 74) and Australia (n = 70), respectively. Genomic instability was quantified by the Total Aberration Index (TAI), a measure of the abundance and genomic size of copy number changes in a tumour. In the Norwegian cohort, patients with TAI above the median revealed sig..

View full abstract


Awarded by U.S. Army Medical Research and Materiel Command

Awarded by National Health and Medical Research Council of Australia (NHMRC)

Awarded by U.S. Department of Defense

Awarded by NHMRC

Funding Acknowledgements

This project was supported by grants from the Norwegian Research Council, the National Cancer Institute of Norway and the Howard Hughes Medical Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Further, the authors wish to thank SMD and the Stanford Functional Genomics Facility for data storage support. The Australian Ovarian Cancer Study was supported by the U.S. Army Medical Research and Materiel Command under DAMD17-01-1-0729, The Cancer Council Victoria, Queensland Cancer Fund, The Cancer Council New South Wales, The Cancer Council South Australia, The Cancer Foundation of Western Australia, The Cancer Council Tasmania and the National Health and Medical Research Council of Australia (NHMRC; ID400413, ID40028). The AOCS BRCA genotyping study was supported by Ovarian Cancer Research Program of the U.S. Department of Defense (W81XWH-08-1-0684 and W81XWH-08-1-0685), Cancer Australia and National Breast Cancer Foundation (509303) and the Peter MacCallum Cancer Centre Foundation. The Gynaecological Oncology Biobank at Westmead is a member bank of the Australasian Biospecimens Network-Oncology, which is funded by NHMRC (ID310670, ID628903). YW was a research fellow of The Norwegian Research Council. MES was supported in part by a Scholar Award from the Marsha Rivkin Center for Ovarian Cancer Research.